When accounting for LOH and repression, 39/132 (30%) of LUAD tumor regions, 3/90 (3%) of LUSC tumor regions and 18/36 (50%) of ER+ breast tumors had all six intact HLA alleles, while 9/132 (7%) of LUAD tumor regions, 18/90 (20%) of LUSC tumor regions and 3/36 (8%) of ER+ breast tumors had all six alleles disrupted at the genomic and transcriptomic levels (Fig. 3d). The gene discussed is ESR1; the disease is neoplasm.